These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 20164596)

  • 1. Comparison of intravenous immunoglobulins for naturally occurring autoantibodies against amyloid-beta.
    Balakrishnan K; Andrei-Selmer LC; Selmer T; Bacher M; Dodel R
    J Alzheimers Dis; 2010; 20(1):135-43. PubMed ID: 20164596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural human antibodies to amyloid beta peptide.
    Szabo P; Relkin N; Weksler ME
    Autoimmun Rev; 2008 Jun; 7(6):415-20. PubMed ID: 18558354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humoral immune response to fibrillar beta-amyloid peptide.
    Miller DL; Currie JR; Mehta PD; Potempska A; Hwang YW; Wegiel J
    Biochemistry; 2003 Oct; 42(40):11682-92. PubMed ID: 14529278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of ELISA measurements of anti-Aβ concentrations and percentages of specific binding to Aβ between unfractionated intravenous immunoglobulin products and their purified anti-Aβ antibodies.
    Klaver AC; Coffey MP; Smith LM; Loeffler DA
    Immunol Lett; 2013; 154(1-2):7-11. PubMed ID: 23928186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral and central biodistribution of (111)In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease.
    Bacher M; Depboylu C; Du Y; Noelker C; Oertel WH; Behr T; Henriksen G; Behe M; Dodel R
    Neurosci Lett; 2009 Jan; 449(3):240-5. PubMed ID: 18786612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naturally occurring autoantibodies against Aβ oligomers exhibited more beneficial effects in the treatment of mouse model of Alzheimer's disease than intravenous immunoglobulin.
    Wang T; Xie XX; Ji M; Wang SW; Zha J; Zhou WW; Yu XL; Wei C; Ma S; Xi ZY; Pang GL; Liu RT
    Neuropharmacology; 2016 Jun; 105():561-576. PubMed ID: 26907803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody concentrations to Abeta1-42 monomer and soluble oligomers in untreated and antibody-antigen-dissociated intravenous immunoglobulin preparations.
    Klaver AC; Finke JM; Digambaranath J; Balasubramaniam M; Loeffler DA
    Int Immunopharmacol; 2010 Jan; 10(1):115-9. PubMed ID: 19840873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurement of anti-Abeta1-42 antibodies in intravenous immunoglobulin with indirect ELISA: the problem of nonspecific binding.
    Klaver AC; Patrias LM; Coffey MP; Finke JM; Loeffler DA
    J Neurosci Methods; 2010 Mar; 187(2):263-9. PubMed ID: 20097229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease.
    Dodel R; Hampel H; Depboylu C; Lin S; Gao F; Schock S; Jäckel S; Wei X; Buerger K; Höft C; Hemmer B; Möller HJ; Farlow M; Oertel WH; Sommer N; Du Y
    Ann Neurol; 2002 Aug; 52(2):253-6. PubMed ID: 12210803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Different Aβ Aggregates as Antigen on the Measure of Naturally Occurring Autoantibodies against Amyloid-β40/42 in IVIG.
    Cao H; Du X; Zeng R; Lv Z; Ye S; Jiang P; Wang Z; Ma L; Huang Y; Li C; Zhang R; Liu F
    Curr Alzheimer Res; 2019; 16(14):1290-1299. PubMed ID: 31894747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease.
    Relkin NR; Szabo P; Adamiak B; Burgut T; Monthe C; Lent RW; Younkin S; Younkin L; Schiff R; Weksler ME
    Neurobiol Aging; 2009 Nov; 30(11):1728-36. PubMed ID: 18294736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zinc binding agonist effect on the recognition of the beta-amyloid (4-10) epitope by anti-beta-amyloid antibodies.
    Zirah S; Stefanescu R; Manea M; Tian X; Cecal R; Kozin SA; Debey P; Rebuffat S; Przybylski M
    Biochem Biophys Res Commun; 2004 Aug; 321(2):324-8. PubMed ID: 15358179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous immunoglobulin and Alzheimer's disease immunotherapy.
    Solomon B
    Curr Opin Mol Ther; 2007 Feb; 9(1):79-85. PubMed ID: 17330405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human monoclonal antibodies against amyloid-beta from healthy adults.
    Geylis V; Kourilov V; Meiner Z; Nennesmo I; Bogdanovic N; Steinitz M
    Neurobiol Aging; 2005 May; 26(5):597-606. PubMed ID: 15708434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naturally occurring autoantibodies against β-Amyloid.
    Bach JP; Dodel R
    Adv Exp Med Biol; 2012; 750():91-9. PubMed ID: 22903668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies.
    Lee M; Bard F; Johnson-Wood K; Lee C; Hu K; Griffith SG; Black RS; Schenk D; Seubert P
    Ann Neurol; 2005 Sep; 58(3):430-5. PubMed ID: 16130106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology.
    Bard F; Barbour R; Cannon C; Carretto R; Fox M; Games D; Guido T; Hoenow K; Hu K; Johnson-Wood K; Khan K; Kholodenko D; Lee C; Lee M; Motter R; Nguyen M; Reed A; Schenk D; Tang P; Vasquez N; Seubert P; Yednock T
    Proc Natl Acad Sci U S A; 2003 Feb; 100(4):2023-8. PubMed ID: 12566568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice.
    Muhs A; Hickman DT; Pihlgren M; Chuard N; Giriens V; Meerschman C; van der Auwera I; van Leuven F; Sugawara M; Weingertner MC; Bechinger B; Greferath R; Kolonko N; Nagel-Steger L; Riesner D; Brady RO; Pfeifer A; Nicolau C
    Proc Natl Acad Sci U S A; 2007 Jun; 104(23):9810-5. PubMed ID: 17517595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extending the functional characteristics of naturally occurring autoantibodies against β-Amyloid, Prion Protein and α-Synuclein.
    Albus A; Gold M; Bach JP; Burg-Roderfeld M; Jördens M; Kirchhein Y; Kronimus Y; Mengel D; Zerr I; Dodel R
    PLoS One; 2018; 13(8):e0202954. PubMed ID: 30157279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenic, antigenic, fibrillogenic and inflammatory properties of new simplified beta-amyloid peptides.
    Rossi M; Piovesan P; Ghirardi O; Mastroianni D; Bombardi V; Battistini L; Cencioni MT; Capobianco D; Borsini F; Colombo M; Verdoliva A
    Mol Immunol; 2009 Aug; 46(13):2524-32. PubMed ID: 19535144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.